Public views on gene editing and its uses by Gaskell, George et al.
  
G. Gaskell, I. Bard, A. Allansdottir, J. Hampel, E. Hildt,  
N. Kronberger, S. Laursen, S. Nordal, A. Quintanilha,  
G. Revuelta, J. Sándor, I. Singh, H. Somsen , H.Torgersen, 
V.Torre, H. Zwart, N. Saladié, R. Vieira da Cunha,  
A. Meijknecht, C. Hofmaier, M. Varju, S. Seyringer,  
P. Eduard, W. Toonders, J. Borlido Santos 
Public views on gene editing and its uses 
Article (Accepted version) 
(Refereed) 
 
 
 
Original citation: 
Gaskell, George and Bard, Imre and Allansdottir, Agnes and da Cunha, Rui Vieira and Eduard, 
Peter and Hampel, Juergen and Hildt, Elisabeth and Hofmaier, Christian and Kronberger, 
Nicole and Laursen, Sheena and Meijknecht, Anna and Nordal, Salvör and Quintanilha, 
Alexandre and Revuelta, Gema and Saladié, Núria and Sándor, Judit and Santos, Júlio 
Borlido and Seyringer, Simone and Singh, Ilina and Somsen, Han and Toonders, 
Winnie and Torgersen, Helge and Torre, Vincent and Varju, Márton and Zwart, Hub (2017)Public 
views on gene editing and its uses. Nature Biotechnology, 35 (11). pp. 1021-1023. ISSN 1087-
0156 
 
DOI: 10.1038/nbt.3958 
 
© 2017 Nature America, Inc., part of Springer Nature. 
 
This version available at: http://eprints.lse.ac.uk/86594/ 
 
Available in LSE Research Online: January 2018 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. Users may download and/or print one copy of any 
article(s) in LSE Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities 
or any commercial gain. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE 
Research Online website.  
 
This document is the author’s final accepted version of the journal article. There may be 
differences between this version and the published version.  You are advised to consult the 
publisher’s version if you wish to cite from it. 
 
 
 
 
 1 
On gene editing and its uses: the views of the public 
 
George Gaskell1, Imre Bard1, Agnes Allansdottir2, Juergen Hampel3, Elisabeth Hildt4 , Nicole 
Kronberger5, Sheena Laursen6, Salvör Nordal7, Alexandre Quintanilha8, Gema Revuelta9, Judit 
Sándor10, Ilina Singh11, Han Somsen12 , Helge Torgersen13, Vincent Torre14, Hub Zwart15, Núria 
Saladié9, Rui Vieira da Cunha8, Anna Meijknecht12, Christian Hofmaier3, Márton Varju10, Simone 
Seyringer5,  Peter Eduard6, Winnie Toonders15, Júlio Borlido Santos8 
 
1Department of Methodology, London School of Economics, London, UK. 
2Toscana Life Sciences Foundation, Siena, Italy. 
3Center for Interdisciplinary Risk and Innovation Studies, Stuttgart University, Germany. 
4Center for the Study of Ethics in the Professions, Illinois Institute of Technology, Chicago USA  
5Department of Social and Economic Psychology Johannes Kepler University, Linz, Austria. 
6Experimentarium, Science Communication Centre, Copenhagen, Denmark. 
7Centre for Ethics University of Iceland, Reykjavik, Iceland. 
8Institute of Molecular and Cellulaor Biology, Porto, Portugal. 
9Centre on Science, Communication and Society Universitat Pompeu Fabra, Spain. 
10The Center for Ethics and Law in Biomedicine Central European University, Budapest, Hungary. 
11Department of Psychiatry and Oxford Uehiro Centre University of Oxford, UK 
12Tilburg Institute for Law, Technology, and Society, Tilburg University, Tilburg, The Netherlands. 
13Institute of Technology Assessment Austrian Academy of Sciences, Vienna, Austria. 
14Centre for Neurobiology, International School for Advanced Studies, Trieste, Italy. 
15Institute for Science, Innovation and Society Radboud University of Nijmegen, The Netherlands. 
 
Correspondence should be to G.G. e-mail: g.gaskell@lse.ac.uk 
 
 
 
 
 
 
 
 
 2 
Abstract 
 
This paper reports on an online contrastive vignette study investigating the public's views of gene 
editing for therapy and enhancement in adult and prenatal contexts. The study, comprising quota 
samples of 1000 respondents per country, involved 10 European countries and the United States. 
Vignettes featuring gene editing for therapy compared to enhancement are seen as more morally 
acceptable and gain more support. Adult therapy attracts majority support, while prenatal 
enhancement elicits almost complete rejection. The assessment of adult enhancement and 
prenatal therapy are more ambivalent. These results and the respondents’ accounts of the 
reasons behind the decision point to a focus on the uses of gene editing, rather than the 
technology itself. The study is a contribution to understanding the practical dimensions of the 
ethical question: how can gene editing contribute to human flourishing? 
 
Public views on gene editing and its uses 
 
Rapid advances in genome editing, including CRISPR-Cas9 endonucleases, and their potential 
application in medicine and enhancement have been hotly debated by scientists and ethicists. 
Although a veto on germ line gene editing has been proposed1, the use of gene editing on human 
cells in the clinical context remains controversial, particularly for interventions aimed at 
enhancement2. In a report on human genome editing the US National Academy of Sciences (NAS) 
note that “important questions raised with respect to genome editing include how to incorporate 
societal values into salient clinical and policy consideration”3. We report here our research that 
opens a window onto what the public think.  
 
We conducted on-line quota sample surveys of 1000+ respondents in Austria, Denmark, Germany, 
Hungary, Iceland, Italy, the Netherlands, Portugal, Spain, UK and the USA (see the Supplementary 
Note, Section 1) to elicit judgments about gene editing using the contrastive vignette method4,5. In 
our study, four vignettes in an experimental design combined two contexts and two recipient 
categories (see the Supplementary Note, Section 2). The contexts were therapy (curing a disease) 
and enhancement (improving memory and learning capacity). The recipient categories were adult 
and prenatal. The vignettes presented brief accounts of situations leading to a decision to use 
gene editing. Each respondent read one of the four vignettes assigned at random and was then 
asked, “Do you think he/they made a morally acceptable decision?” and “In his/their shoes would 
you make the same choice?” Responses were recorded on an 11 point scale (from –5 = ‘No, 
definitely’ not to +5 ‘Yes, definitely’). Comparing the responses across vignettes reveals the effect 
of the experimental manipulations. 
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A multiple regression analysis (see Table 1) shows that the ‘therapy ’ vignettes compared with 
‘enhancement’ vignettes have on average higher scores on moral acceptability and on agreement 
that the respondent would make the same choice (to use gene editing) by over 4 points in the 11 
point scale. The ‘prenatal’ compared with the ‘adult’ recipient elicits a lower assessment of both 
moral acceptability, and whether the respondent would make the same choice. Adding age, 
gender and education level of the respondents to the regression showed only that female 
respondents are more cautious about gene editing in general.  
 
Table 1: Regression coefficients for the target and purpose of gene editing.  
See Supplementary Note, Table 1 for country level results 
Response variable Adult 
compared with 
prenatal 
Enhancement 
compared with 
therapy 
(R2) % of variance in 
‘would you make the 
same choice’  
accounted for by the 
model.  
Is it morally acceptable? 1.89** –3.68** 0.36 
Would you make the same 
choice? 
1.47** –4.34** 0.37 
 
** p<0.001 
Across the eleven countries in the study support is consistently greater for treatment than 
enhancement (between 3.3 and 5.2 scale points). Similarly, across all countries there is greater 
support for intervention on adults than prenatals, but the magnitude effect of the target recipient 
is smaller (between 1.0 and 2.1 scale points). This is in agreement with the NAS report that there 
are “indications of public discomfort with using genome editing for what is deemed to be 
enhancement”.   
 
A notable feature of the responses to the vignettes is how the range of opinion varies across the 
targets and purposes of the intervention (see Fig. 1).  
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Figure 1: Would you make the same decision? Box plots of responses to each gene editing 
vignette 
 
For both ‘adult therapy’ and ‘prenatal enhancement’ the responses show a broad agreement. The 
former is accepted with a median response of eight, whereas the latter is rejected with a median 
response just above zero. In contrast, ‘adult enhancement’ and ‘prenatal therapy’ appear to be 
morally ambiguous, reflected in very diverse opinions. 50% of the responses range over about half 
of the 11 point scale.  
 
To explore the respondents’ thinking we asked: “In a few words, can you tell us why you agree or 
disagree with the decision”. Almost three out of four people added comments, suggesting that the 
topic is of importance. A systematic content analysis identified 21 broad themes. (See the 
Supplementary Note, Section 3). For ‘adult therapy’, 75% of the comments are positive 
evaluations of gene editing technology; in order of frequency: improvements to quality of life; 
curing dementia; and the benefits outweighing the risks. For ‘prenatal therapy’ the proportion of 
support for gene editing declines to 60%. The positive content is the same as for ‘adult therapy,’ 
with the additional comment: it is natural for parents to want the best for their children. Gene 
editing for ‘Adult enhancement’ achieves only 26% positive comments. On the negative side 
people mention there is no need; being normal or average is OK, and that there might be risks and 
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unknown consequences. ‘Pre-natal enhancement’ elicits only 11% positive comments. In order of 
frequency the negative remarks say gene editing is: unnatural and messing with nature; there is no 
need; there are risks of unknown consequences; and it is just wrong.  
 
Might previous debates around modern biotech carry over into people’s thinking about gene 
editing? For example, do respondents view gene editing through a critical lens of genetically 
modified organisms (GMOs)? The answer is no; fewer than 3% mentioned GMOs. Other issues 
that did not feature beyond 1% or 2% included designer babies and some of the ethical questions 
around human enhancement—increasing social disparities, obtaining an unfair advantage and 
undermining character. 
 
Turning to differences between countries, Figure 2 shows the median scores for the four 
experimental vignettes. 
Figure 2: National differences on ‘Would you make the same decision?’ 
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‘EEA_10’ is the aggregate over the 10 European countries. We show the median rather than the 
mean because in some countries at least half of the respondents gave a zero for the enhancement 
vignettes. The differing assessments of ‘therapy ’ (between 5 and 9) versus ‘enhancement’ 
(between 0 and 4) highlight the fact that it is the application, rather than the technology itself, 
that is the critical issue for the public. Gene editing as applied to ‘adult therapy ’ receives 
consistent support across all countries. And although there are differences between countries 
over the use of gene editing for ‘prenatal therapy’, it is supported in the majority of countries. 
More than half of the sample in Austria, Denmark, Germany, Hungary, Iceland, Italy the 
Netherland, Portugal and the UK say they would not use gene editing for pre-natal enhancement. 
This pattern is also seen in Austria, Denmark and Germany for ‘adult enhancement’.  
 
Across the countries, a stronger precautionary judgment is evident for gene editing for therapy 
and enhancement in the prenatal compared with the adult scenario. This is somewhat counter-
intuitive. For example, assuming successful use in the therapeutic context, gene editing at the 
prenatal stage will have greater positive impact on the future outcomes of the recipient, simply 
because the recipient will live fewer years with a medical disability, compared with intervention in 
adulthood. In the enhancement context, prenatal intervention will arguably cause less distress 
than in the adult context. In adults, concerns about the violation of the sense of self, or of 
personal authenticity, are often presented as reasons to avoid enhancement6,7. Concerns about 
authenticity violations in the prenatal context are likely to be less compelling to many people, 
although there may be other ethical considerations that again tip the balance. Such issues will 
need to be critically interrogated in the deliberation over the uses of gene-editing technology. 
Although the US public joins people in the UK and Spain in being a little less negative than other 
EEA10 countries about adult enhancement, differences between the US the EEA10 countries are 
notable by their absence. 
 
As with many other technologies, the public’s attention is on the applications or uses; these drive 
moral judgments. Yet scientific experts tend to focus on the technology as such. This harks back to 
the old struggle between regulating the process (the technology) or the applications (uses of the 
technology) that has caused so many problems for agricultural biotech in Europe8. Focusing on the 
technology will lead to inconsistent regulation, always lagging behind scientific progress.  Focusing 
on uses will also present challenges: if countries opt for different regulations on the uses and 
target recipients of gene editing, some people may take to medical tourism. Should policy 
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prioritize national interests or be transnational to reduce the risks associated with diverging 
policies? Perhaps it is time to set up a multinational institutional structure to guide innovative 
technological applications that are societally contentious. 
A final word on the value of surveys in this controversial territory. Public opinion cannot and 
should not tell us what is right to do. However, as the NAS report notes “Public participation 
should be incorporated into the policy-making process for human genome editing and should 
include ongoing monitoring of public attitudes, informational deficits, and emerging concerns 
about issues surrounding enhancement.” This survey is a contribution to understanding the 
practical and contextual dimensions of the ethical question; how can gene-editing technology 
contribute to human flourishing? 
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Supplementary notes 
 
Section 1:  The survey design and procedures 
 
Respondi  coordinates double opt-in access panels of respondents for online surveys.  The sample 
size for this study  was specified at circa 1000 and selected to reflect the gender, age and 
education profile of those 18 years and older in each country.  The number of invitations sent out 
to achieve 1000 completed and quality interviews took account of the expected response rate; on 
average 25 per cent. 
 
Section 2:  Genome Editing Experimental Vignettes 
 
(Adult therapy) 
Please read this story carefully. 
John has dementia. Among other symptoms, his short-term memory and learning capacities are 
slowly getting worse. John learns about a new gene-editing technology that has been developed. 
It would rewrite the gene sequence in some affected cells, and could delay or prevent his memory 
and learning decline. He decides to undergo the therapeutic genetic modification. 
 
(Prenatal therapy) 
Please read this story carefully. 
John and Sarah are expecting a baby. The couple is informed that their child will inherit a tendency 
to develop dementia. Later in the child’s life, this will result in slowly worsening cognitive abilities, 
including short term memory and learning capacities. They also learn about a new gene-editing 
technology that would re-write some relevant genetic sequences before the baby is born. As a 
result, the later risk of memory and learning decline is significantly lower. They decide to use the 
therapeutic genetic modification. 
 
(Adult enhancement) 
Please read this story carefully. 
John is a healthy adult with average short-term memory and learning capacities. John learns about 
a new gene-editing technology that has been developed. It would rewrite some relevant genetic 
sequences, and could improve his memory and learning capacities. He decides to undergo the 
enhancing genetic modification. 
 
(Prenatal enhancement) 
Please read this story carefully. 
John and Sarah are expecting a baby. The couple is informed that their child will be healthy with 
normal cognitive abilities. They also learn about a new gene-editing technology that would re-
write some relevant genetic sequences before the baby is born. As a result, the child’s memory 
and learning capacities could be enhanced. They decide to use the 
enhancing genetic modification. 
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Instructions and response alternatives 
Please read the following questions and drag the slider to indicate your answer. If your answer to 
a question leans towards 'yes', then you drag to the right side of the scale, from 1 to 5. The 
stronger your agreement, the closer you would be to 5. Conversely, if you lean towards 'no', then 
you drag the slider to the left side of the scale, and the more strongly you feel about this, the 
closer you would be to -5. 
 
Do you think John/the couple made a morally acceptable decision? 
 
 In John’s/ the couple’s shoes, would you make the same choice? 
 
In a few words, can you tell us why you agree or disagree with John’s/ the couple's decision? 
 
The vignettes and the accompanying questionnaire were designed by the research group.  
Translation from English into the national languages was undertaken by members of the research 
group, all of whom speak English as a first or second language.  Assiduous attention was paid to 
ensuring comparability of meaning of words and phrases. 
 
 
Section 3: Coding frame for content analysis of open ended question “in a few words. Can you 
tell us why you agree or disagree with the decision?” 
 
1 Support – unqualified statement 
2 Support mentioning therapy, improving quality of life 
3 Support mentioning safety/ benefits outweigh risks 
4 
Support mentioning  natural for self/parents to want 
best 
5 Support mentioning autonomy/ individual choice 
6 Uncertain, can’t decide 
7 Wrong - unqualified 
8 Immoral, unethical 
9 No need – normal or average OK 
10 Only used for diseases 
11 Unlikely to work – low efficacy 
12 
Playing god, unnatural, messing with nature, accept 
fate 
13 GM wrong, non-reversible, against evolution 
14 Risks, unknown unintended consequences 
15 Designer babies, master race, Nazis, Frankenstein 
16 Obtaining an unfair advantage 
17 Parents have no right to impose on child 
18 Increase social disparities 
19 Would be abused/doping 
20 
Undermines character, improvement from effort not 
drugs 
21 Other 
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Supplementary Table 1. Gene Editing Vignettes – Regression coefficients by country 
 
Country Response variable Adult vs. 
prenatal  
Enhancement vs. 
therapy 
R2 
 
Austria 
Is it morally acceptable? 1.974** -3.595** 0.33 
Would you make the same choice? 1.482** -3.847** 0.30 
 
Denmark 
Is it morally acceptable? 2.094** -4.216** 0.44 
Would you make the same choice? 1.399** -5.168** 0.49 
 
Germany 
Is it morally acceptable? 1.995** -3.981** 0.38 
Would you make the same choice? 1.240** -4.509** 0.37 
 
Hungary 
Is it morally acceptable? 2.193** -3.994** 0.38 
Would you make the same choice? 1.435** -4.853** 0.40 
 
Iceland 
Is it morally acceptable? 2.102** -3.654** 0.39 
Would you make the same choice? 1.733** -4.526** 0.42 
 
Italy 
Is it morally acceptable? 1.344** -3.907** 0.36 
Would you make the same choice? 1.003** -4.441** 0.37 
The 
Netherlands 
Is it morally acceptable? 1.581** -3.613** 0.37 
Would you make the same choice? 1.364** -3.976** 0.35 
Portugal Is it morally acceptable? 1.648** -3.473** 0.35 
Would you make the same choice? 1.415** -4.557** 0.39 
 
Spain 
Is it morally acceptable? 1.689** -3.603** 0.37 
Would you make the same choice? 1.309** -4.607** 0.42 
United 
Kingdom 
Is it morally acceptable? 2.458** -3.438** 0.39 
Would you make the same choice? 2.299** -3.953** 0.37 
United Is it morally acceptable? 1.752** -2.978** 0.26 
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States Would you make the same choice? 1.452** -3.305** 0.25 
* p<0.05 
** p<0.001 
